Literature DB >> 33463623

Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy.

Raja Narayanan1, Mudit Tyagi1, Shashank R Gupta2, Ashraya Nayaka3, Chaitra Jayadev4.   

Abstract

Entities:  

Year:  2021        PMID： 33463623      PMCID： PMC7933883          DOI： 10.4103/ijo.IJO_3436_20

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN： 0301-4738            Impact factor:   1.848


× No keyword cloud information.
  3 in total

1.  Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.

Authors:  Caroline R Baumal; Richard F Spaide; Lejla Vajzovic; K Bailey Freund; Scott D Walter; Vishak John; Ryan Rich; Nauman Chaudhry; Rohit R Lakhanpal; Patrick R Oellers; Thellea K Leveque; Bryan K Rutledge; Mark Chittum; Tommaso Bacci; Ana Bety Enriquez; Newman J Sund; Eric N P Subong; Thomas A Albini
Journal:  Ophthalmology       Date:  2020-04-25       Impact factor: 12.079

Review 2.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

3.  HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Authors:  Pravin U Dugel; Rishi P Singh; Adrian Koh; Yuichiro Ogura; Georges Weissgerber; Kinfemichael Gedif; Glenn J Jaffe; Ramin Tadayoni; Ursula Schmidt-Erfurth; Frank G Holz
Journal:  Ophthalmology       Date:  2020-06-20       Impact factor: 12.079
  3 in total
  4 in total

1.  Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation.

Authors:  Sentaro Kusuhara; Kyung Woo Kim; Akiko Miki; Makoto Nakamura
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-14

2.  Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders.

Authors:  Sabyasachi Sengupta
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

Review 3.  Side Effects of Brolucizumab.

Authors:  Tahmineh Motevasseli; Saeed Mohammadi; Fatemeh Abdi; William R Freeman
Journal:  J Ophthalmic Vis Res       Date:  2021-10-25

Review 4.  A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.

Authors:  Frank G Holz; Tomohiro Iida; Ichiro Maruko; SriniVas R Sadda
Journal:  Retina       Date:  2022-06-13       Impact factor: 3.975
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.